Multicenter phase 2 trial of rituximab for Waldenström macroglobulinemia (WM): an Eastern Cooperative Oncology Group Study (E3A98).

Multicenter phase 2 trial of rituximab for Waldenström macroglobulinemia (WM): an Eastern Cooperative Oncology Group Study (E3A98). Leuk Lymphoma. 2004 Oct; 45(10):2047-55.

View in: PubMed

subject areas

Aged
Aged, 80 and over
Antibodies, Monoclonal
Antibodies, Monoclonal, Murine-Derived
Female
Humans
Male
Middle Aged
Probability
Rituximab
Survival Analysis
Treatment Outcome
Waldenstrom Macroglobulinemia

authors with profiles

Lynne S. Kaminer